GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (NAS:GERN) » Definitions » EV-to-EBIT

Geron (GERN) EV-to-EBIT

: -11.08 (As of Today)
View and export this data going back to 1996. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Geron's Enterprise Value is $1,948.70 Mil. Geron's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-175.82 Mil. Therefore, Geron's EV-to-EBIT for today is -11.08.

The historical rank and industry rank for Geron's EV-to-EBIT or its related term are showing as below:

GERN' s EV-to-EBIT Range Over the Past 10 Years
Min: -2044.86   Med: -5.46   Max: 5049.58
Current: -11.05

During the past 13 years, the highest EV-to-EBIT of Geron was 5049.58. The lowest was -2044.86. And the median was -5.46.

GERN's EV-to-EBIT is ranked worse than
100% of 440 companies
in the Biotechnology industry
Industry Median: 8.685 vs GERN: -11.05

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Geron's Enterprise Value for the quarter that ended in Dec. 2023 was $901.96 Mil. Geron's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-175.82 Mil. Geron's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -19.49%.


Geron EV-to-EBIT Historical Data

The historical data trend for Geron's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.97 -4.37 -2.37 -6.13 -5.13

Geron Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.13 -5.46 -8.33 -5.35 -5.13

Competitive Comparison

For the Biotechnology subindustry, Geron's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geron EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Geron's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Geron's EV-to-EBIT falls into.



Geron EV-to-EBIT Calculation

Geron's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1948.700/-175.815
=-11.08

Geron's current Enterprise Value is $1,948.70 Mil.
Geron's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-175.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geron  (NAS:GERN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Geron's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-175.815/901.96432
=-19.49 %

Geron's Enterprise Value for the quarter that ended in Dec. 2023 was $901.96 Mil.
Geron's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-175.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geron EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Geron's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Geron (GERN) Business Description

Traded in Other Exchanges
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.
Executives
Michelle Robertson officer: EVP, Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Scott Alan Samuels officer: EVP, Chief Legal Officer 919 E. HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
V Bryan Lawlis director
Susan Molineaux director C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
John A Scarlett director, officer: Chief Executive Officer C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Andrew J Grethlein officer: EVP, Technical Operations 651 GATEWAY BLVD STE 950, SOUTH SAN FRANCISCO CA 94080
Olivia Kyusuk Bloom officer: Controller, Chief Acctg Off C/O GERON CORP, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
John F Mcdonald director C/O GERON CORPORATION, 919 EAST HILLSDALE BLVD., SUITE 250, FOSTER CITY CA 94404
Faye Feller officer: EVP, Chief Medical Officer 919 EAST HILLSDALE BOULEVARD, SUITE 250, FOSTER CITY CA 94404
Anil Kapur officer: EVP, Corp Strategy & CCO 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Melissa Kelly officer: VP, Oncology 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Dawn Carter Bir director C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Aleksandra Rizo officer: EVP, Chief Medical Officer C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025